Invicro and iThera Medical Announce a Strategic Partnership to Enhance in vivo Imaging Capabilities with the MSOT inVision Optoacoustic Imaging Platform

BOSTON & MUNICH–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/biomarkers?src=hash” target=”_blank”gt;#biomarkerslt;/agt;–Invicro LLC, a Konica Minolta company and iTheraMedical GmbH announced a
unique partnership with the placement of the MSOT inVision platform in
Invicro’s in vivo laboratory out of its Boston headquarters. Both
companies will come together to uniquely offer Pharmaceutical, Biotech
and Academia sponsors services from the optoacoustic platform that will
identify and quantify disease-related biomarkers at both a molecular and
anatomical level through pre-clinical full body tomographic scans.

Invicro is a leading provider of quantitative imaging biomarkers, core
lab services and software solutions for research and drug development,
and Munich-based iThera Medical develops unique multispectral
optoacoustic imaging technologies enabling non-invasive, real-time
visualization of anatomical, functional and molecular information in
living tissue at high spatial resolution. This collaboration will
deliver more versatile and accurate imaging biomarkers for preclinical
drug discovery research, while reducing the duration and costs of
biopharmaceutical drug development.

“We are pleased to partner with iThera Medical to jointly offer enhanced
pre-clinical imaging capabilities with the MSOT inVision platform,” said
Ms. Ciara Finucane, MSc, Senior Director and Business Leader of
Discovery Research at Invicro. “Combining iThera Medical’s technology
with Invicro’s advanced quantitative imaging biomarkers offers our
Pharma and Biotech sponsors a comprehensive and efficient solution to
answer their research questions faster.”

“With this partnership, iThera Medical and Invicro continue to
strengthen their strategy jointly to offer global pharma, biotech, and
academic research communities the industry’s most premium imaging,
analytics and technology solutions to support the complete drug
discovery value chain,” stated Mr. Tullio Giannitti, General Manager,
Americas at iThera Medical. “This collaboration is further proof of the
value that MSOT imaging brings to clients in drug discovery. Invicro’s
strategic imaging services align with iThera Medical’s vision,
technologies and industry experience. We are pleased to have the
opportunity to collaborate with the global leader in imaging biomarker
services.”

About iThera Medical
iThera Medical GmbH develops and
markets a novel in-vivo biomedical imaging technology, “MSOT” =
multispectral optoacoustic tomography. MSOT utilizes the photoacoustic
effect to visualize and quantify anatomical, functional and molecular
information in living tissue. Today, MSOT allows the early and reliable
validation of new substance efficacy in drug discovery (e.g., for
oncology, neurology and cardio-vascular problems). In the future, MSOT
also promises to become a valuable tool in clinical diagnostics. iThera
Medical is headquartered in Munich, Germany with a US subsidiary in
Boston.

About Invicro
Headquartered in Boston, MA, Invicro was
founded in 2008 with the mission of improving the role and function of
imaging in translational drug discovery and development across all
therapeutic areas. Today, Invicro’s multi-disciplinary team provides
solutions to pharmaceutical and biotech companies across all stages of
the drug development pipeline (Phase 0-IV), all imaging modalities and
all therapeutic areas, including neurology, oncology, cardiology, and
pulmonary. Invicro’s quantitative biomarker services, advanced analytics
and AI tools, and clinical operational services are backed by Invicro’s
industry-leading software informatics platforms, VivoQuant®
and iPACS®.

As part of the Konica Minolta precision medicine organization and with
their sister company Ambry Genetics, Invicro develops and leverages the
latest approaches in quantitative biomarkers including imaging,
quantitative pathology and genomics. For more information, visit www.invicro.com.

About Konica Minolta
Konica Minolta, Inc. (Konica Minolta)
is a global digital technology company with core strengths in imaging
and data analysis, optics, materials, and nano-fabrication. Through
innovation, Konica Minolta creates products and digital solutions for
the betterment of business and society—today and for generations to
come. Across its Business Technologies, Healthcare, and
Industrial-facing businesses, the company aspires to be an Integral
Value Provider that applies the full range of its expertise to offer
comprehensive solutions to the customer’s most pressing problems, works
with the partners to ensure the solutions are sustainable, anticipates
and addresses tomorrow’s issues, and tailors each solution to meet the
unique and specific needs of its valued customers. Leveraging these
capabilities, Konica Minolta contributes to productivity improvement and
workflow change for its customers and provides leading-edge service
solutions in the IoT era. Headquartered in Tokyo and with operations in
more than 50 countries, Konica Minolta has more than 43,000 employees
serving approximately two million customers in over 150 countries.
Konica Minolta is listed on the Tokyo Stock Exchange, (TSE4902). For
further information, visit: https://www.konicaminolta.com/.

Contacts

Amanda Harrell
VP, Global Marketing
[email protected]

error: Content is protected !!